Publications

 

Publications related to AVISE CTD/AVISE Lupus

AVISE Lupus is indicated for the diagnosis of suspected SLE patients. AVISE CTD is indicated for differential diagnosis of autoimmune connective tissue diseases.

Clinical Validity

Ramsey-Goldman R, et al. Arthritis & Rheumatology. 2019. Complement activation occurs in patients with probable systemic lupus erythematosus and may predict progression to ACR classified SLE.

View Publication


Wallace D, et al. Lupus Science & Medicine. 2016. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.

View Publication


Putterman C, et al. Lupus Science & Medicine. 2014. Cell bound complement activation products in systemic lupus erythematosus.

View Publication

Clinical Utility

Alexander RV, et al. Lupus Science & Medicine. 2021. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. 

View Publication


Wallace D, et al. Lupus Science & Medicine. 2019. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. 

View Publication


Liang E, et al. Lupus Science & Medicine. 2020. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression.

View Publication


Mossell J, et al. Open Rheumatology Journal. November 2016. The AVISE Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.

View Publication

Health Economic Outcome Research

Clarke et al. ACR Open Rheumatology. 2020. Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP).

View Publication

Analytical Validity

Dervieux et al. Journal of Immunological Methods. 2017. Validation of multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.

View Publication

SLE Review Articles

Mosca M, et al. Arthritis & Rheumatology. 2019. How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria.

View Publication


Meacock R, Dale N, Harrison MJ et al. Pharmacoeconomics. 2013. The humanistic and economic burden of systemic lupus erythematosus: A systematic review. Pharmacoeconomics.

View Publication

Case Study

Lamichhane D, Weinstein A et al. Lupus. 2016. Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS).

View Publication

Medical Society Guidelines

Aggarwal, Rohit et al. Arthritis Care & Research. 2015. Distinctions between diagnostic and classification criteria?

View Publication

AVISE SLE Monitor is indicated for the ongoing assessment of SLE disease activity

Clinical Validity

Kao A, Navratil J, Ruffing M, et al. Arthritis and Rheumatology. 2010. Erythrocyte C3d and C4d for Monitoring Disease Activity in Systemic Lupus Erythematosus.

View Publication


Buyon J, Furie R, Putterman C, et al. Lupus Science & Medicine. 2016. Reduction in erythrocyte-bound complement activation products and titers of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.

View Publication


Merrill JT, Petri MA, Buyon J, et al. Lupus Science & Medicine. 2018. Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

View Publication


Mahler M, Bentow C, O’Malley T, et al. Journal of Immunology Research. 2017. Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus.

View Publication


Orbai AM, Truedsson L, Sturfelt G, et al. Lupus. 2015. Anti-C1q antibodies in systemic lupus erythematosus.

View Publication


Akhter E, Burlingame R, Seaman A, et al. Lupus. 2012. Anti-C1q antibodies have a higher correlation with flares of lupus nephritis than other serum markers.

View Publication


Svenungsson E, Gustafsson JT, Grosso G, et al. Rheumatology. 2020. Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus.

View Publication


Petri MA, Conklin J, O'Malley T, et al. Lupus Science and Medicine. 2019. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE Lupus Science & Medicine.

View Publication


Kao AH, McBurney CA, Sattar A, et. al. Transl. Stroke Research. 2014. Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.

View Publication


Publications related to CB-CAPs

Clinical Validity

Manzi et al. Arthritis & Rheumatism. 2004. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.

View Publication


Kao AH et al. Arthritis & Rheumatism. 2010. Navratil JS, Ruffing MJ, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum.

View Publication


Liu CC, Kao AH, Hawkins DM, Manzi S, Sattar A, Wilson N, Ahearn JM et al. Clinical and Translational Science. 2009. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clin Transl Sci.

View Publication


Yang et al. Rheumatology. 2009. Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus.

View Publication

Analytical Validity

Dervieux T et al. Journal of Immunological Methods. 2017. Validation of multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.

View Publication


CB-CAPs Review Articles

Ramsey-Goldman R, Li J, Dervieux T, et al. Lupus Science and Medicine. 2017. Cell-bound complement activation products in SLE. Lupus Science & Medicine.

View Publication


Ahearn et al. Expert Review of Clinical Rheumatology. 2017. Cell-bond complement activation products as lupus biomarkers: diagnosis, monitoring and stratification.

View Publication

PC4d is indicated for diagnosed SLE patients as a marker associated with thrombosis.

Clinical Validity

Elisabet Svenungsson et al. Rheumatology. 2020. Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus.

View Publication


Petri MA, Conklin J, O'Malley T, et al. Lupus Science and Medicine. 2019. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE Lupus Science & Medicine.

View Publication


Kao AH, McBurney CA, Sattar A, Lertratanakul A, Wilson NL, Rutman S, Paul B, Navratil JS, Scioscia A, Ahearn JM, Manzi S. et. al. Transl. Stroke Research. 2014. Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.

View Publication

Avise MTX is indicated for RA patients receiving Methotrexate therapy as an objective measure of therapeutic exposure.

Clinical Validity

Takahashi C, Kaneko Y, Okano Y, et al. RMD Open. 2017. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study.

View Publication


Dervieux et al. Rheumatology. 2010. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.

View Publication


Dervieux et al. Annals of the Rheumatic Diseases. 2005. Pharmacogentic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentered cross-sectional observation study.

View Publication


Dervieux et al. Arthritis and Rheumatology. 2006. Pharmacogenomic and Metabolic Biomarkers in the Folate Pathway and Their Association With Methotrexate Effects During Dosage Escalation in Rheumatoid Arthritis.

View Publication

AVISE MTX Review Articles

Braun J. et al. Therapeutic Advances in Musculoskeletal Disease. 2011. Methotrexate: Optimizing the Efficacy in Rheumatoid Arthritis. Therapeutic Advances in Musculoskeletal Disease.

View Publication


Kremer J. et al. Arthritis & Rheumatology. 2004. Toward a Better Understanding of Methotrexate. Arthritis and Rheum.

View Publication

Analytical Validity

Kelley Brady et al. The Journal of Applied Laboratory Medicine. 2019. Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases.

View Publication

AVISE HCQ is indicated for SLE patients receiving Hydroxychloroquine therapy as an objective measure of therapeutic exposure.

Clinical Validity

Petri et al. Arthritis & Rheumatology. 2019. Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.

View Publication


Costedoat-Chalumeau et al. American Society for Clinical Pharmacology and Therapeutics. 2017. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.

View Publication


Costedoat Chalumeau N et al. Annals of the Rheumatic Diseases. 2013. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).

View Publication


Costedoat-Chalumeau N et al. Very Low Blood Hydroxychloroquine Concentration As an Objective Marker of Poor Adherence to Treatment of Systemic Lupus Erythematosus.

View Publication

AVISE HCQ Review Articles

Garg et al. Arthritis Care & Research. 2020. The Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

View Publication


Laura Durcan, William A. Clarke, Laurence S. Magder, Michelle Petri et al. The Journal of Rheumatology. 2015. Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence

View Publication

Analytical Validation

Qu et al. J Pharm Biomed Anal. 2017. Capillary blood collected on volumetric absorptive microsampling (VAMS) device for monitoring hydroxychloroquine in rheumatoid arthritis patients.

View Publication

Arriens C, Alexander RV, Narain S, et al. Lupus Science & Medicine. 2020. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science & Medicine.

View Publication


Hui-Yen et al. Lupus. 2018. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.

View Publication

Abstracts

Petri M, Li J, Conklin J, O'Malley T, Ligayon J, Wolover L, Dervieux T. et al. Arthritis Rheumatol. 2020. Role of Platelet C4d in Thrombosis and Lupus Nephritis [abstract].

View Publication


Gartshteyn Y, Mor A, Shimbo D, Khalili L, Kapoor T, Geraldino-Pardilla L, Alexander R, Dervieux T, Askanase A. et al. Arthritis Rheumatol. 2020. Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events [abstract].

View Publication


Gartshteyn Y, Alexander R, Conklin J, Dervieux T, Askanase A. et al. Arthritis Rheumatol. 2020. Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE [abstract].

View Publication


Gartshteyn Y, Mor A, Geraldino L, Kapoor T, Chen T, Dervieux T, Askanase A. et al. Arthritis Rheumatol. 2019. Platelet Bound Complement Split Product (PC4d) May Be a Marker of Platelet Activation and Cardiovascular Events in Systemic Lupus Erythematosus [abstract].

View Publication


Petri M, Li J, Brady K, Conklin J, O'Malley T, Dervieux T. et al. Arthritis Rheumatol. 2020. Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory [abstract].

View Publication


Balbi V, Silva C, Pedrosa T, Pereira R, Campos L, Leon E, Duarte N, Carvalho V, Pasoto S, Rosario D, Brandao L, Bonfa E, Aikawa N. et al. Arthritis Rheumatol. 2020. Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis [abstract].

View Publication


Dervieux T, Kremer J, Brady K, Takahashi C, Takeuchi T, Kaneko Y. et al. Arthritis Rheumatol. 2019. Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate [abstract].

View Publication


Garg S, Unnithan R, Hansen K, Costedoat-Chalumeau N, Bartels C. et al. Arthritis Rheumatol. 2019. Meta-Analysis Examining the Clinical Significance of Monitoring of Hydroxychloroquine Levels in SLE [abstract].

View Publication


Petri M, Elkhalifa M, Goldman D, Magder LS, Singh M. et al. Arthritis Rheumatol. 2018. Hydroxychloroquine Blood Levels Show Significant Trend Test for Risk of Retinopathy [abstract].

View Publication


Dervieux T, Kremer J, Brady K, Takahashi C, Takeuchi T, Kaneko Y. et al. Arthritis Rheumatol. 2019. Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate [abstract].

View Publication


Dervieux T, Grosjean M, Jiang C, Brady K, Schmiegelow K, Kremer J, Yang J. et al. Arthritis Rheumatol. 2018. Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis [abstract].

View Publication


Dervieux T, Kremer JM, O'Malley T, Kivitz AJ, Conklin J, Weinblatt M. et al. Arthritis Rheumatol. 2016. Differing Contribution of Methotrexate Polyglutamation to Infliximab and Adalimumab Exposure As Compared to Etanercept [abstract].

View Publication

Methotrexate polyglutamates (MTXPGs)

Brady K, et al. American Association for Clinical Chemistry. 2019. Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases.

View Publication


Dervieux T, et al. Annals of the Rheumatic Diseases 2018. Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.

View Publication


Dervieux T, et al. Annals of the Rheumatic Diseases 2012. Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis.

View Publication


Dervieux T, et al. Annals of the Rheumatic Diseases. 2005. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.

View Publication


Dervieux T, et al. Arthritis & Rheumatism. 2006. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.

View Publication


Kremer J. Arthritis & Rheumatism. 2004. Toward a better understanding of methotrexate.

View Publication


Dervieux T, et al. Clinical Chemistry. 2003. HPLC Determination of Erythrocyte Methotrexate Polyglutamates after Low-Dose Methotrexate Therapy in Patients with Rheumatoid Arthritis.

View Publications

Anti-Carbamylated Protein Antibodies (Anti-CarP)

Weinstein A, et al. The Journal of Rheumatology. 2019. Reevaluating Serologic Markers of Poor Prognostic Factors in Rheumatoid Arthritis.

View Publication


Shi J, et al. PNAS. 2011. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.

View Publication

 

Abstracts

An Evaluation of the Economic Impact of Earlier Systemic Lupus Erythematosus  (SLE) Diagnosis Using Complement C4D Activation Products in a Multivariate Assay.

View Abstract


ACR Chicago 2018. Capillary Blood Based Methotrexate Polyglutamate Assay for Monitoring Low Dose Methotrexate Therapy in Rheumatic Diseases.

View Abstract


ACR Chicago 2018. Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis.

View Abstract


ACR Chicago 2018 Complement C4d Split Products in Combination With lupus Anticoagulant and Low Complement Associate With Thrombosis in Systemic lupus erythematosus.

View Abstract


ACR San Diego 2017. Abnormalities in Complement System are Related to Disease Severity Index in Systemic lupus erythematosus.

View Abstract


ACR Chicago 2018 Diagnostic Performances of Antibodies Against Carbamylated Proteins in U.S. Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases

View Abstract


ACR San Diego 2017. Complement Activation in Peripheral Blood in Relation to lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights From Clinical Laboratory Evaluations.

View Abstract


ACR San Diego 2017. Abnormalities in Complement System are Related to Disease Severity Index in Systemic lupus erythematosus.

View Abstract


ACR San Diego 2017. Cell bound Complement Activation Products Distinguish systemic lupus erythematosus From Other Diseases Among Patients With High Antinuclear Antibody Titers and Normal Complement.

View Abstract


ACR Chicago 2018 Diagnostic Performances of Antibodies Against Carbamylated Proteins in U.S. Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases.

View Abstract


ACR San Diego 2017. Complement Activation in Peripheral Blood in Relation to lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights From Clinical Laboratory Evaluations.

View Abstract


ACR San Diego 2017. A Panel of lupus Biomarkers for the Monitoring of systemic lupus erythematosus: Performance Characteristics in Distinct SLE Cohorts.

View Abstract


ACR San Diego 2017. Cell bound Complement Activation Products Distinguish systemic lupus erythematosus From Other Diseases Among Patients With High Antinuclear Antibody Titers and Normal Complement.

View Abstract